Date: 2011-06-13
Type of information: Fundraising
Company: Haemostatix (UK)
Investors: Esperante Ventures (UK)
Amount: £250,000 (€284,000)
Funding type: financing round
Planned used: Haemostats are used by surgeons to manage problematic bleeding and to reduce time in the operating theatre during surgery. The products are applied in the form of sprays, gels or pads, and typically contain the enzyme thrombin, which promotes blood clotting, as the active ingredient. Haemostatix has developed a new class of active ingredient based on a peptide that binds to another blood clotting protein, fibrinogen, instantly forming a clot.
Others: Haemostatix received an investment of £250,000 from Esperante to support development of its innovative haemostat technology. This is the third round of funding the Company has secured in the last 12 months.
Therapeutic area: Technology - Services - Hemostasis